Você procurou por: jirovecii (Inglês - Estoniano)

pneumocystis jirovecii pneumonia
pneumocystis jirovecii pneumoonia

infections (including pneumocystis jirovecii pneumonia and cmv)*
infektsioonid (sh pneumocystis jirovecii põhjustatud pneumoonia ja tsütomegaloviirus)

a includes pneumocystis jirovecii (carinii) pneumonia (pjp, pcp)
a sealhulgas pneumocystis jirovecii (carinii) põhjustatud pneumoonia (pjp, pcp)

pneumocystis jirovecii pneumonia (pcp) prophylaxis was required during rt and combined tmz therapy.
pjp profülaktika oli vajalik nii rt kui ka tmz-i kombineeritud ravi ajal.

relevant examples are cytomegalovirus retinitis, generalised and/or focal mycobacterial infections, and pneumocystis jirovecii pneumonia.
vastavad näited on tsütomegaloviiruse poolt põhjustatud retiniit, generaliseerunud ja/või fokaalsed mükobakteriaalsed infektsioonid ja pneumocystis jirovecii pneumoonia.

as you should be observed closely for the development of a serious form of chest infection called pneumocystis jirovecii pneumonia (pcp).
kuna teid tuleb tähelepanelikult jälgida raskekujulise kopsupõletiku tekkimise suhtes rindkeres, mida nimetatakse pneumocystis jirovecii pneumooniaks (pjp).

all patients treated with zydelig should be given preventive medication against the lung infection pneumocystis jirovecii pneumonia during treatment, and this should be continued for up to 6 months after treatment with zydelig has stopped.
kõik patsiendid, kes saavad zydeligiga toimuvat ravi, peavad kasutama ravi ajal pneumocystis jirovecii tekitatava kopsuinfektsiooni vastast ennetavat ravimit, mille kasutamist tuleb jätkata kuni 6 kuud pärast zydeligiga toimuva ravi lõppu.

patients who received concomitant tmz and rt in a pilot trial for the prolonged 42 day schedule were shown to be at particular risk for developing pneumocystis jirovecii pneumonia (pcp).
patsiendid, kes said pikemaajalises 42-päevases pilootuuringus tmz kombineeritult rt-ga, olid eriti kõrge riskiga pneumocystis jirovecii pneumoonia (pcp) tekkeks.

positive exams for pneumonia with virus or particular germs (e.g. legionella, aspergillus, mycobacteria, mycoplasma, pneumocystis jirovecii)
viiruse või teatavate haigustekitajate (nt legionella, aspergillus, mükobakterid, mycoplasma, pneumocystis jirovecii) põhjustatud kopsupõletiku kindlakstegemine;

patients who received concomitant tmz and rt in a pilot trial for the prolonged 42-day schedule were shown to be at particular risk for developing pneumocystis jirovecii pneumonia (pcp).
patsiendid, kes said pikemaajalises 42-päevases pilootuuringus tmz-d kombineeritult radioteraapiaga, olid eriti disponeeritud pneumocystis jirovecii pneumoonia (pcp) tekkeriskile.

talk to your doctor, pharmacist or nurse before taking temomedac, as you should be observed closely for the development of a serious form of chest infection called pneumocystis jirovecii pneumonia (pcp).
enne temomedaci võtmist pidage nõu oma arsti, apteekri või meditsiiniõega, kuna teid tuleb tähelepanelikult jälgida raskekujulise põletiku tekkimise suhtes, mida nimetatakse pneumocystis jirovecii pneumooniaks (pjp).

cases of pneumocystis jirovecii (carinii) pneumonia (pjp, pcp), some with fatal outcome, have been reported in patients who received everolimus.
everoliimust saanud patsientidel on teatatud pneumocystis jirovecii (carinii) põhjustatud pneumoonia (pjp, pcp) juhtudest, mõnel juhul surmlõppega.